Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 916

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 916
---
 Company effectuated a 1-for-12 reverse stock split of our common stock (the “1:12
Reverse Stock Split” and together, with the 1:5 Reverse Stock Split, the “Reverse Stock Splits”). Beginning August 12,
2024, our common stock traded on The Nasdaq Capital Market on a split adjusted basis.

All common share and applicable per share amounts in this Annual Report
on Form 10-K have been retroactively restated to reflect the effect of the Reverse Stock Splits.

Transfer Agent

The transfer agent for our common stock is Equity
Stock Transfer, LLC (“Equity Stock Transfer”), located at 237 West 37th Street, Suite 602, New York, NY 10018. The phone
number and facsimile number for Equity Stock Transfer are (212) 575-5757 and (347) 584-3644, respectively. Additional information about
Equity Stock Transfer can be found on its website at www.equitystock.com.

Dividend Policy

We have never paid any cash dividends on our
common stock. We anticipate that we will retain funds and future earnings to support operations and to finance the growth and development
of our business. Therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination to pay dividends
will be at the discretion of our Board and will depend on our financial condition, results of operations, capital requirements, and other
factors that our Board deems relevant. In addition, the terms of any future debt or credit financings may preclude us from paying dividends.

Unregistered Sales of Equity Securities

Common Stock

    ●
    On July 22, 2024 and July 26,
                                    2024, we issued 8,000 and 6,667 shares of common stock to Knight, respectively, upon conversion of
                                    1,291 and 1,032 shares of Series A Preferred Stock, respectively, at the conversion price detailed
                                    in Note 6 to the accompanying consolidated financial statements.

    ●
    From October 2024 to January 2025,
                                    we issued an aggregate of 579,711 shares of common stock upon the exercise of pre-funded warrants
                                    issued to investors in the September 2024 private placement.

The issuances of shares of common stock listed
above were deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that
the issuance of securities